Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Genzyme, a Sanofi Company | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.
Screening will be done prior to enrollment in the study. The following will be done as part of the screening process:
If the patient is ineligible or does not have a donor for Allogeneic Stem Cell transplantation, you will not be able to participate in this clinical trial.
After results of these tests are obtained, your doctor will decide whether you can participate in this study.
Study procedures:
The study drug will be given for 5 days.
Days 1 through 5:
The patient will receive dexamethasone 1.5 hours prior to the administration of Clofarabine as part of standard care for subjects receiving Clofarabine.
The patient will receive an intravenous (IV) injection (into the vein) of Clofarabine each day for 5 days. This injection is given in the hospital and will be given over approximately 60 minutes each day. The actual dose of Clofarabine is based on the weight and height of the subject.
The patient will have the following tests done to see the effects of the study drug:
Each day of Clofarabine administration, on day 12 and then each day until stem cell transplantation:
Day 12 after Clofarabine administration and then as outlined for stem cell transplantation:
• Bone marrow biopsy and aspirate.
After Clofarabine administration, there will be short resting period of 7-14 days. After the resting period, the patient will start receiving conditioning chemotherapy regimen (other standard of care drugs to better prepare your body for the stem cell transplant). This regimen will begin 15-21 days after they first received Clofarabine, and consists of additional treatment (chemotherapy and/or radiation). The type of treatment(s) the patient will receive for conditioning is dependent on the type of disease. In addition, this treatment will be decided by your doctor and is independent of this research. The duration of the conditioning period is variable and may take between 5-8 days. Stem cells are usually given one day after the completion of this regimen, which will be between 21 and 30 days after the patient has first received Clofarabine.
Follow-up Subjects who have a response and proceed with stem cell transplant will be followed weekly for the first three months and then every month for six months, then every two months for 12 months, then every three months for 18 months. The stem cell transplant will be done 21-30 days after first receiving Clofarabine. Subjects who do not go on to stem cell transplant will be followed for 3 months following administration of Clofarabine.
At these visits, the following will be done:
End of study
At this time, the following tests will be done:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Clofarabine | Experimental | Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clofarabine | Drug | Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line. |
| Measure | Description | Time Frame |
|---|---|---|
| Cytoreductive Response | Percent of patients achieving cytoreductive response of marrow cellularity <20% and blasts < 10% | Day 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Renal Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Day 12 |
| Number of Participants With Hepatic (Total Bilirubin) Adverse Events |
Not provided
Inclusion Criteria:
Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
Adequate hepatobiliary function as indicated by the following laboratory values:
Age >/=18 years
Zebroid performance status \
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wendy Stock, MD | University of Chicago | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Chicago hospitals | Chicago | Illinois | 60637 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Clofarabine | Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days Clofarabine: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Clofarabine | Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days Clofarabine: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cytoreductive Response | Percent of patients achieving cytoreductive response of marrow cellularity <20% and blasts < 10% | Posted | Number | percentage of participants | Day 12 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Clofarabine | Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days Clofarabine: Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Renal (creatine) | Renal and urinary disorders |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Renal (creatinine) | Renal and urinary disorders |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Wendy Stock, MD | The University of Chicago | 773-834-8982 | wstock@medicine.bsd.uchicago.edu |
Not provided
| ID | Term |
|---|---|
| D007938 | Leukemia |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077866 | Clofarabine |
| ID | Term |
|---|---|
| D000227 | Adenine Nucleotides |
| D011685 | Purine Nucleotides |
| D011687 | Purines |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
| Day 12 |
| Number of Participants With Hepatic (SGOT) Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Day 12 |
| Number of Participants With Cardiac Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Day 12 |
| Number of Participants With Skin Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Day 12 |
| Number of Participants Infection Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Day 12 |
| Leukemia Free Survival | Time to event analysis used the day of transplant as day 0. | 2 years |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
|
|
| Secondary | Number of Participants With Renal Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Posted | Number | participants | Day 12 |
|
|
|
| Secondary | Number of Participants With Hepatic (Total Bilirubin) Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Posted | Number | participants | Day 12 |
|
|
|
| Secondary | Number of Participants With Hepatic (SGOT) Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Posted | Number | participants | Day 12 |
|
|
|
| Secondary | Number of Participants With Cardiac Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Posted | Number | participants | Day 12 |
|
|
|
| Secondary | Number of Participants With Skin Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Posted | Number | participants | Day 12 |
|
|
|
| Secondary | Number of Participants Infection Adverse Events | Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. | Posted | Number | participants | Day 12 |
|
|
|
| Secondary | Leukemia Free Survival | Time to event analysis used the day of transplant as day 0. | One patient with refractory AML underwent conditioning but died 1 day before stem cell infusion due to sepsis (grade 5 infection) | Posted | Median | 95% Confidence Interval | days | 2 years |
|
|
|
| 22 |
| 29 |
| 26 |
| 29 |
| Hepatic (total bilirubin) | Hepatobiliary disorders |
|
| Hepatic (SGOT) | Hepatobiliary disorders |
|
| Infection | Infections and infestations |
|
| Hepatic (total bilirubin) | Hepatobiliary disorders |
|
| Hepatic (SGOT) | Hepatobiliary disorders |
|
| Cardiac | Cardiac disorders |
|
| Skin | Skin and subcutaneous tissue disorders |
|
Not provided
Not provided
| D000072471 |
| Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D001087 | Arabinonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D009711 | Nucleotides |
| D012265 | Ribonucleotides |